What is he best known for?
The fields of study he is best known for:
Daniel C. Koboldt focuses on Genetics, Mutation, Gene, Cancer research and Haplotype.
His research related to Human genome, Genetic association, Exome sequencing, Genome and Genomics might be considered part of Genetics.
His work deals with themes such as Computational biology and Epigenetics, which intersect with Genomics.
His specific area of interest is Gene, where Daniel C. Koboldt studies DNA methylation.
His research integrates issues of Leukemia and microRNA in his study of Cancer research.
His studies examine the connections between Haplotype and genetics, as well as such issues in Single-nucleotide polymorphism, with regards to Selection and Natural selection.
His most cited work include:
- A global reference for human genetic variation. (7825 citations)
- Comprehensive molecular portraits of human breast tumours (7253 citations)
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways (5484 citations)
What are the main themes of his work throughout his whole career to date?
Daniel C. Koboldt mainly investigates Genetics, Genome, Mutation, Gene and Whole genome sequencing.
His research on Genetics often connects related areas such as Computational biology.
His Genome research incorporates elements of Mutation and Indel.
His studies deal with areas such as Cancer, Breast cancer and Cancer research, Myeloid leukemia as well as Mutation.
His study in Cancer research is interdisciplinary in nature, drawing from both microRNA, Immunology, DNA methylation and Bioinformatics.
He works mostly in the field of Whole genome sequencing, limiting it down to topics relating to Massive parallel sequencing and, in certain cases, Data science.
He most often published in these fields:
- Genetics (65.14%)
- Genome (20.18%)
- Mutation (20.18%)
What were the highlights of his more recent work (between 2015-2021)?
- Genetics (65.14%)
- Exome sequencing (15.60%)
- Somatic cell (5.50%)
In recent papers he was focusing on the following fields of study:
Daniel C. Koboldt spends much of his time researching Genetics, Exome sequencing, Somatic cell, Computational biology and Cancer research.
Daniel C. Koboldt performs integrative study on Genetics and IRF6.
His Exome sequencing research includes themes of BRCA2 Protein, Prostate cancer and Bioinformatics.
His Somatic cell research is multidisciplinary, relying on both Phenotype, Whole genome sequencing and Gene expression profiling.
His Computational biology study integrates concerns from other disciplines, such as Exome, Vascular malformation and DNA sequencing.
His studies in Cancer research integrate themes in fields like Second Malignancy, microRNA, DNA and Profiling.
Between 2015 and 2021, his most popular works were:
- The Alzheimer's Disease Sequencing Project: Study design and sample selection. (50 citations)
- IRF6 mutation screening in non‐syndromic orofacial clefting: analysis of 1521 families (27 citations)
- DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas. (23 citations)
In his most recent research, the most cited papers focused on:
The scientist’s investigation covers issues in Genetics, Exome sequencing, Epidemiology, Copy-number variation and Gene duplication.
Daniel C. Koboldt merges Genetics with IRF6 in his research.
The Exome sequencing study combines topics in areas such as Precision medicine, Gene expression profiling, Bioinformatics and Somatic cell.
Daniel C. Koboldt interconnects Dementia and Gerontology in the investigation of issues within Epidemiology.
His Gerontology research is multidisciplinary, incorporating elements of Alzheimer's disease, Disease and Public health.
The various areas that Daniel C. Koboldt examines in his Copy-number variation study include Tandem exon duplication, Locus, Sanger sequencing, Massive parallel sequencing and Haplotype.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
